Search Results for "Alnylam"

Alnylam is committed to providing the healthcare community with balanced, accurate, and high-quality information about our science, therapeutic areas, and products.

More than one search term is recommended to yield the most relevant results. By searching, you confirm that your query is unsolicited.

For more information about our FDA-approved therapies, please see the Full Prescribing Information:

ATTR Disease Management

This deck highlights management and monitoring of patients with ATTR.

ATTRv-PN Expert Opinion Slide Deck

Recommendations from a panel of experts for the diagnosis and treatment of hereditary transthyretin amyloidosis with polyneuropathy in the United States.

Subgroup Results from KARDIA-2: Impact of Demographic and Baseline Disease Characteristics on Zilebesiran Response in Patients with Hypertension Uncontrolled by a Standard Oral Antihypertensive

The Science of RNAi

KARDIA-3 Study Design: Zilebesiran as Add-On Therapy in Patients with High Cardiovascular Risk and Hypertension Inadequately Controlled by Standard of Care Antihypertensives

Potential Predictors of PH1 in Pediatric Patients

The handout details potential clinical characteristics that pediatric patients may present with which should warrant suspicion for PH1.

Likelihood of disease worsening in patients receiving tafamidis for ATTR amyloidosis with cardiomyopathy (ATTR-CM): A targeted literature review

Durable Reductions in Circulating Angiotensinogen and Blood Pressure 6 Months after Single Doses of ALN-AGT, an RNA Interference Therapeutic Targeting Hepatic Angiotensinogen Synthesis, in Hypertensive Patients

ATTR Diagnostic and Staging Tools

This deck highlights diagnostic and staging tools for assessing patients with ATTR.

For further information regarding your request, please connect with us by reaching out to your local Medical Science Liaison or contacting our Medical Information team.